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Abstract
Background: Keratin polypeptide 19 (K19) is a type I intermediate filament protein that is expressed in stratified and simple-
type epithelia. Although K19 is known to be phosphorylated on tyrosine residue(s), conclusive site-specific characterization
of these residue(s) and identification potential kinases that may be involved has not been reported.
Methodology/Principal Findings: In this study, biochemical, molecular and immunological approaches were undertaken in
order to identify and characterize K19 tyrosine phosphorylation. Upon treatment with pervanadate, a tyrosine phosphatase
inhibitor, human K19 (hK19) was phosphorylated on tyrosine 391, located in the ‘tail’ domain of the protein. K19 Y391
phosphorylation was confirmed using site-directed mutagenesis and cell transfection coupled with the generation of a K19
phospho (p)-Y391-specific rabbit antibody. The antibody also recognized mouse phospho-K19 (K19 pY394). This tyrosine
residue is not phosphorylated under basal conditions, but becomes phosphorylated in the presence of Src kinase in vitro
and in cells expressing constitutively-active Src. Pervanadate treatment in vivo resulted in phosphorylation of K19 Y394 and
Y391 in colonic epithelial cells of non-transgenic mice and hK19-overexpressing mice, respectively.
Conclusions/Significance: Human K19 tyrosine 391 is phosphorylated, potentially by Src kinase, and is the first well-defined
tyrosine phosphorylation site of any keratin protein. The lack of detection of K19 pY391 in the absence of tyrosine
phosphatase inhibition suggests that its phosphorylation is highly dynamic.
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Introduction
Intermediate filaments (IFs) encompass a large group of nuclear
and tissue-specific cytoplasmic proteins and are major components
of the eukaryotic cytoskeleton [1–2]. Among the cytoplasmic IFs,
keratins (K) are expressed in epithelial cells in a cell-specific
manner, and have a characteristic IF molecular structure that
consists of a central coiled-coil a helical domain (termed ‘rod’) that
is flanked by non-a-helical N-terminal (‘head’) and C-terminal
(‘tail’) domains [3]. Keratins include more than 50 unique gene
products that are classified into type I (K9-K28, K31-K40) and
type II (K1-K8, K71-K86), which associate non-covalently with
each other at a 1:1 ratio to form heteropolymers [4]. The various
epithelial cell types express specific keratin heteropolymers. For
example, keratinocytes preferentially express K5/K14 or K1/
K10, depending on their differentiation state in the epidermis,
adult hepatocytes express K8/K18 exclusively, and intestinal
epithelial cells express K8, along with varying levels of K18/K19/
K20 [2–3,5]. K19 is a type I IF protein that is expressed in
stratified and simple-type epithelia, such as the small intestine,
colon, exocrine pancreas, bladder, gallbladder, and the ductal cells
of the liver [6]. It is unique among the other keratins because it has
a very short amino acid tail domain [7–8].
Appreciation for the physiological significance of keratins is
continually growing as a result of the identification of a significant
number of human diseases linked to keratin mutations [9–13] and
the generation of keratin-null and mutant keratin-expressing
transgenic mouse lines [14]. Keratins carry out both mechanical
and non-mechanical cellular functions, including maintenance of
cell integrity, positioning of subcellular organelles, signaling, and
protection from injury and apoptosis [3,15–17]. An important
mechanism whereby these diverse functions are regulated is via
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to date, is the most studied type of modification in keratins [18–
19]. Keratin phosphorylation is a highly dynamic process that
occurs mostly within the ‘head’ and ‘tail’ domains, which harbor
most of the structural heterogeneity of these proteins.
Previous work regarding the phosphorylation of K19 demon-
strated that head domain residue serine-35 is a major phosphor-
ylation site [20] and that K19 expressed by various cell lines and
primary mouse colon epithelial cells undergoes tyrosine phos-
phorylation upon treatment with pervanadate, a potent tyrosine
phosphatase inhibitor [21]. The latter finding is of particular
interest since, relative to serine and threonine phosphorylation,
tyrosine phosphorylation of IFs is less common, except in the case
of vimentin and peripherin [22–24], and has not been well
characterized in the case of the keratins. In this study we have used
molecular, biochemical and immunologic tools to demonstrate
that the human K19 tail domain is phosphorylated at tyrosine-391
(Y391) upon phosphatase inhibition in cultured cells and intact
tissues. Moreover, Src tyrosine kinase phosphorylates K19 Y391 in




HT29 (human colon), NIH-3T3 (mouse fibroblast) and BHK-
21 (baby hamster kidney) cells were obtained from the American
Type Culture Collection (ATCC). NIH-3T3 cells stably transfect-
ed with either vector (pcDNA3.1) or constitutively-active Y527F
Src kinase were previously established and described [25]. The
antibodies used were: mouse monoclonal antibody (mAb) L2A1,
which recognizes human K18 [26], mAb 4.62 (Sigma), which
recognizes human K19, and mAb Troma III (University of Iowa
Hybridoma Bank) which recognizes mouse K19. The pan anti-
phosphotyrosine (pY) antibody used was mAb PY-20 (Invitrogen),
and the anti-Src antibody used was mAb-327 (Oncogene). Sodium
vanadate (Fisher Scientific, Pittsburg, PA) was used to prepare
pervanadate (PV) by mixing with hydrogen peroxide in phosphate-
buffered saline (PBS) and used within 1 hr of preparation as
described previously [21]. The protein tyrosine phosphatase
inhibitors BVT 948, TCS 401, NSC 87877 and NSC 95397
were purchased from Tocris and used as described in the figure
legend.
Mouse experiments
The nontransgenic FVB/n strain (control) and the transgenic
mice overexpressing wild type human K19 (hK19; on FVB/n
background) were cared for, and used, according to standard
institutional guidelines. Pre-sedated three month old mice were
injected with 200 mL of saline or PV (5mM vanadate/50 mM
H2O2) rectally by using a flexible plastic tube. The mice were
sacrificed one hour later by CO2 inhalation and their colons were
dissected and divided into 3 parts, which were subsequently used
for: (i) Hematoxylin and eosin (H&E) staining, (ii) Immunofluo-
rescence staining, or (iii) Immune blotting. The immunofluores-
cence and histology staining procedures were carried out as
described [27]. All mice received humane care and their use was
approved by the Institutional Animal Care Committee at the Palo
Alto Veterans Administration (approval number OMA070210-
MOU).
Antibody generation and characterization
The rabbit anti-phospho-epitope polyclonal antibody (K19 pY)
was generated against the K19 peptide CGQEDHpYNNLSA
(Anaspec). This peptide corresponds to human pTyr391 and
mouse pTyr394-containing K19. The Cys residue, which is not
part of the K19 sequence, was added to the N-terminus of the
peptide sequence to facilitate coupling to keyhole limpet
hemocyanin. Two rabbit antibodies (Ab 3866 and Ab 3867) were
generated, but the second and third bleeds of Ab 3866 showed
superior reactivity to K19 pY and this antibody was further
purified and used for all of the experiments described herein.
Immunoprecipitation and gel analysis
HT29 cells were solubilized in 1% Nonidet P40 (NP40) in PBS
containing 5 mM EDTA and a protease inhibitor cocktail (Sigma).
Keratins were immunoprecipitated using antibodies L2A1 and
4.62, and the immunoprecipitates were analyzed by: (i) SDS-
polyacrylamide gel electrophoresis (PAGE) followed by transfer to
polyvinylidene fluoride (PVDF) membranes for immunoblotting,
and by (ii) isoelectric focusing (IEF), SDS-PAGE and transfer to
PVDF membranes for immunoblotting.
Mutagenesis and transfection
Site-directed mutagenesis of human K19 cDNA (GenBank
accession number NM_002276.4) to convert Tyr391RPhe, and
Tyr4RPhe was performed using QuikChange kit (Stratagene) and
confirmed by DNA sequencing. Transfections into BHK-21 and
NIH-3T3 cells were performed using lipofectamine reagent
(Invitrogen) with wild type (WT) or mutant K19 cDNA plus
WT human K8 cDNA (GenBank accession number NM_
002273.3). Whole cell lysates from the transfected cells were
loaded onto one dimensional (1D) SDS-PAGE or two dimensional
(2D) IEF/ SDS-PAGE separation gels for immunoblotting.
In vitro phosphorylation using Src kinase
Reactions using the Src kinase kit were performed according to
the manufacturer’s instructions (Millipore). Briefly, immunopre-
cipitated K19 was added to the kinase buffer containing 8 mM
MOPS-NaOH (pH 7.0), 10 mM MnCl2, 1 mM DTT, and 2 mM
ATP, in the presence or absence of Src kinase (50 ng) in a total
reaction volume of 25 ml. Following an incubation of the reaction
mixture at 30uC for 10 min, 2% SDS-containing or urea-
containing sample buffer was added for either the 1D or 2D gel
electrophoresis analysis, respectively.
Results
Identification of Tyr391 as a phosphorylation site in
human K19
The NetPhos version 2.0 server (http://www.cbs.dtu.dk/
services/NetPhos/) was utilized in predicting putative tyrosine
phosphorylation sites in the human K19 protein (K19). The search
from this neural network-based method yielded several sites in the
head domain (Tyr4, Tyr6 and Tyr61) and one site in the tail
domain (Tyr391) of K19 that could potentially undergo phos-
phorylation (Table S1).
Based on the prediction scores that were assigned to the tyrosine
residues (Table S1), site-directed mutagenesis was performed on
the K19 cDNA to convert Tyr4RPhe (K19 Y4F), Tyr391RPhe
(K19 Y391F), and Tyr4,391RPhe (K19 Y4/391F). Following
sequencing analysis to confirm the mutation results, BHK-21 cells
were transfected with the cDNA of K19 wild type (K19 WT) or
one of the mutants. Additionally, the cDNA of wild type human
K8 (K8 WT) was co-transfected in each case to allow for
stabilization of the transfected keratins as occurs with the normal
co-expression of type I and type II keratins [28]. After a 90-min
treatment of the transfected cells with pervanadate (PV), an
K19 Phosphorylation by Src
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lysates were prepared and subjected to one (1D) or two
dimensional (2D) gel electrophoresis and immune blotting using
anti-K19 or anti-pan phosphotyrosine (pY) antibodies. Protein
expression was confirmed (Figure 1A) and equal amounts of K19
were subjected to 2D analysis.
As demonstrated in Figure 1B, there were two spots detected by
the hK19 antibody, including one with an acidic shift (labeled ‘‘2’’)
that was also detected by the anti-pan pY antibody upon analysis
of the K19 WT-transfected cell lysates. This was similar to the
results obtained with the K19 Y4F-transfected cell lysates
(Figure 1), suggesting that Tyr4 in the head domain of K19 is
not phosphorylated upon PV cell treatment. In contrast,
transfection of either K19 Y391F, or K19 Y4/391F in the
BHK-21 cells led to a loss in the phosphotyrosine signal, although
a single spot on the 2D gel, representing the presence of K19
protein, was detected in each case. These results demonstrate that
Tyr391 in the human K19 protein is phosphorylated in the
presence of PV, thereby suggesting that this residue may be
phosphorylated under physiological or pathological conditions.
Characterization of a K19 Tyr-391 using a phospho-
epitope-specific antibody
In order to determine more conclusively that Tyr391 is a
phosphorylation site in K19, a rabbit antibody specifically
recognizing K19 pY391 was developed and characterized. Shown
in Figure 2A is the sequence alignment of the human and mouse
K19 tail domains with the peptide antigen that was used to
generate the anti-K19 pY391 antibody. Due to the very short K19
tail domain, Y391 is in close proximity to the rod domain of the
protein.
To test the specificity of the antibody, lysates of either untreated
or PV-treated HT29 cells were used in immunoblot experiments
with 1D or 2D gel electrophoresis. As shown in Figure 2B,
although total K19 (using antibody 4.62) was detected in the
lysates from both the untreated and the PV-treated cells, the anti-
K19 pY391 antibody specifically recognized a band only in the
lysates of the PV-treated cells. Similarly, by using 2D gel
electrophoresis to separate the proteins, the anti-K19 pY391
antibody detected a signal in the lysates from the PV-treated cells
(dots labeled 2 and 3), but not in the lysates from the untreated
cells. As a further confirmation of the specificity of the K19 pY
antibody to Tyr391, lysates of PV-treated BHK-21 cells that had
been previously transfected with the cDNAs of K8 WT together
with, either K19 WT, K19 Y4F, or K19 Y391F, were subjected to
western blot analysis. As demonstrated in Figure 2D, the K19 pY
signal was absent only in the K19 Y391F- transfected cell lysates,
thus confirming the specificity of the K19 pY antibody to Tyr391.
The anti-K19 pY391 antibody was also used to determine the
distribution of K19 pY391 between the soluble and insoluble
compartments of HT29 cells, which, respectively, were the
supernatant and pellet fractions after lysis of the cells in 1%
NP40 detergent [29]. An increase in total K19 is observed in the
soluble fraction (antibody 4.62-reactive species) after treatment
with PV (Figure 3). K19 pY391 was detected only in the soluble
fractions in a time-dependent manner, such that 45 min of PV
treatment resulted in significantly more K19 pY391, relative to the
shorter treatment of 15 min.
In vitro phosphorylation of Tyr391 by Src kinase
Since tyrosine phosphorylation of target proteins can be carried
out either in a receptor-dependent or receptor-independent
manner, a number of potential pathways that could lead to K19
Tyr391 phosphorylation were investigated. Stimulation of several
tyrosine kinase receptor pathways in HT29 cells, including the
epidermal growth factor receptor and the insulin receptor, did not
induce detectable K19 Y391 phosphorylation (data not shown),
suggesting a lack of involvement of these two signaling pathways in
the context of this cell line.
In contrast, K19 was phosphorylated on Tyr391 while in the
presence of the non-receptor tyrosine kinase Src under both in
vitro and in vivo cell culture conditions, as shown in Figure 4. In
vitro Src-mediated phosphorylation of K19 was detected upon
incubation of human K19, which was immunoprecipitated from
HT29 cells using two different antibodies (4.62 and L2A1)
(Figure 4A). Additionally, the acidic isoforms reflecting phosphor-
ylated K19 (spots 1 and 2), detected by the anti-K19 pY391
antibody were detected upon 2D gel electrophoresis separation of
the in vitro kinase reaction components containing Src and
immunoprecipitated human K19 (Figure 4B).
To investigate K19 tyrosine phosphorylation in cell culture
conditions, murine fibroblast NIH-3T3 cells stably expressing
either constitutively-active Y527F Src, or empty vector, were co-
transfected with the DNA of K8 (WT) and K19 (either WT or
Y391F). As shown in Figure 5, K19 was phosphorylated at Tyr391
Figure 1. Human K19 is phosphorylated on ‘tail’ domain
tyrosine-391. BHK-21 cells were co-transfected with wild type (WT)
K8 and one of four K19 constructs (WT, Y4F, Y391F, or Y4,391F). The
transfected cells were treated with 1 mM PV for 90 min, then harvested
and lysed. A. Whole cell lysates were initially analyzed by 1D gel
electrophoresis followed immunoblotting using mAb 4.62 (which
recognizes total K19) to confirm expression. B. For the 2D gel analysis
(equal K19 protein loading), isoelectric focusing (IEF) was done in the
first dimension followed by SDS page in the second dimension.
Immunoblots for total K19 (4.62 mAb) and pan-pY (mAb PY20) are
shown and the corresponding phospho-isoforms are labeled as ‘1’ and
‘2’.
doi:10.1371/journal.pone.0013538.g001
K19 Phosphorylation by Src
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not the Y391F, K19 protein. These experiments demonstrate that
K19 undergoes Src kinase-mediated phosphorylation at Tyr391
under cell-free and cell culture conditions.
Exposure of mouse colon to PV increases K19 tyrosine
phosphorylation
A prior study demonstrated that injection of PV rectally into
mice results in significant keratin tyrosine phosphorylation in colon
tissue, as determined by using anti-pan pY antibody (22).
Therefore, using non-transgenic FVB/n (control) or transgenic
mice overexpressing human K19 (hK19), similar experiments were
carried out to determine whether Tyr391 of K19 is phosphory-
lated in tissues after exposure to PV. As shown in Figure 6A, a
phosphorylated form of K19 was detected in the colon tissue
obtained from both the FVB/n and the hK19 mice treated with
PV, but not saline. Hence, the anti-pY391 K19 antibody that was
developed also recognizes the corresponding mouse pY394
residue, located in the tail domain (Figure 2A).
As demonstrated by the hematoxylin and eosin (H&E) staining,
exposure of mouse colon to PV resulted in edema and injury of the
epithelium and breakage of the epithelial cells along the mucosal
folds (Figure 6B). Comparison of the immunofluorescence staining
of the colon tissue from the hK19 mice treated with either saline
(control) or PV, revealed significant up-regulation of K19 pY391/
pY394 in epithelial cells that express K19 (Figure 6C). These data
demonstrate that mK19 and hK19 undergo pervanadate-depen-
dent phosphorylation in vivo at Tyr394 and Tyr391, respectively.
Discussion
Intermediate filaments are highly dynamic structures in living
cells. The protein subunits are constantly undergoing a process of
Figure 2. Characterization of a rabbit polyclonal anti-phospho K19 tyrosine 391 (K19 pY391) antibody. A. The amino acid sequence of
the phospho-peptide used for immunizing rabbits is shown. The peptide antigen is aligned with the human and mouse K19 tail sequences. B.
Resolution of whole cell lysate proteins from untreated and pervanadate (PV)-treated HT29 cells using standard 1D SDS-PAGE followed by blotting
with the antibodies directed towards total K19 (mAb 4.62) and phospho-K19 (rabbit anti-K19 pY391). C. The same HT29 cell lysates as those used in
panel B were resolved using 2D IEF/SDS-PAGE. The K19 pY391 antibody recognizes two acidic K19 isoforms (spots 2 and 3) only in PV-treated, but not
control cells. Total K19, as detected by antibody 4.62 is present in control and PV-treated cells. D. Whole cell lysates of PV-treated BHK-21 cells
transfected with K19 WT, Y4F, or Y391F were resolved using a 1D gel or 2D gel (IEF then SDS-PAGE) and blotted with anti-K19 (to confirm expression;
lower panel) and anti-K19 pY391 (upper panels), respectively.
doi:10.1371/journal.pone.0013538.g002
K19 Phosphorylation by Src
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upon a variety of stimuli particularly those related to oxidative
stress, apoptosis-inducing or exposure to toxins [30]. One
established mechanism by which the keratin assembly and
distribution is modulated is via phosphorylation by protein Ser/
Thr kinases and dephosphorylation by protein phosphatases to
promote, respectively, filament disassembly and reassembly [18–
19]. In addition to Ser/Thr phosphatase inhibition, Tyr
phosphatase inhibition also results in significant keratin filament
reorganization although this is related, at least in significant part,
to modulation of keratin Ser/Thr phosphorylation [31].
For keratins and other intermediate filament proteins, phos-
phorylation on tyrosine residues is markedly underrepresented
relative to phosphorylation on serine residues. The phosphotyr-
osine content of epidermal keratins was barely detected when
compared with the phosphoserine content [32]. It was previously
shown that K8 and K19 are phosphorylated on tyrosine residues
after treatment with the potent and irreversible tyrosine phospha-
Figure 3. Detergent-based fractionation and distribution of
K19 pY391. HT-29 cells were cultured with or without PV treatment
for the indicated times. Cells were then solubilized in 1% NP40 for 45
minutes, followed by collection of the supernatant (S) and pellet (P)
fractions. Each fraction was suspended in equal volume of sample
buffer followed by analysis by SDS-PAGE and immunoblotting using
antibodies to the indicated antigens. Note the time-dependent
partitioning of K19 pY to the soluble fraction upon treatment with PV.
doi:10.1371/journal.pone.0013538.g003
Figure 4. In vitro phosphorylation of K19 by Src kinase. A. Keratins were immunoprecipitated from HT29 cells using two different antibodies
(4.62 and L2A1). In vitro kinase assays using Src kinase were then carried out as described in Materials and Methods. Samples were analyzed by SDS-
PAGE and immunoblotting using antibodies to total K19 (4.62) and to phospho-K19 (anti-K19 pY391). B. Kinase reaction products of HT29 K19
immunoprecipitate (using 4.62 antibody) and Src were resolved by 2D IEF/SDS-PAGE gel then blotted for total K19 (4.62 antibody) and K19 pY391.
Note that the anti-K19 pY391 antibody does not recognize the more basic K19 isoforms (within bracket) that are recognized by the 4.62 antibody.
doi:10.1371/journal.pone.0013538.g004
Figure 5. Tyrosine phosphorylation of K19 in NIH-3T3 cells
expressing constitutively-active Y527F Src kinase. NIH-3T3 cells
stably expressing either empty vector (Vector) or active Src kinase (Src-
active) were co-transfected with wild type (WT) K8 and, either K19 WT,
or K19 Y391F. Whole cell lysates were prepared from the transfected
cells and resolved on SDS-PAGE gels followed by blotting with
antibodies to the indicated antigens. Src-dependent phosphorylation
of K19 WT, but not K19 Y391F, is observed.
doi:10.1371/journal.pone.0013538.g005
K19 Phosphorylation by Src
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32PO4 and phosphoamino acid analysis, as well as anti-
phosphotyrosine antibodies [21]. The findings herein demonstrate
that this modification takes place on Tyr391 in the tail domain of
human K19 and the corresponding residue, Tyr394, in the tail
domain of mouse K19. In addition to mouse and human, this
tyrosine residue is conserved in rat (Tyr394), primate (Tyr391),
and bovine (Tyr389) K19, but not in chicken (Figure S1),
suggesting a possible mammalian-specific role for phosphorylation
at this site. Additionally, this modification is likely to be unique to
K19 since sequence comparison of human K19 to other type I
human keratins shows a lack of conservation for Tyr391. In this
study, Tyr391 phosphorylation of human K19 was demonstrated
by the use of a phospho-specific antibody recognizing the specific
modification in PV-treated cells and mice. Based on in vitro cell-
based assays, this phosphorylation could be mediated by Src kinase
or possibly a related family member, although the latter was not
tested.
Both type I (K18 and K19) and type II (K5-K8) keratins were
identified as substrates for oncogenic tyrosine kinases in a large-
Figure 6. Treatment of mice with pervanadate unmasks tyrosine phosphorylation of K19. Mice were treated with PV as described in
Materials and Methods. A. Colon tissue lysates (solubilized in 4X SDS-containing sample buffer) from untreated or PV-treated FVB/n (control) and
human K19 over-expressing (hK19) transgenic mice were resolved on SDS-PAGE gels and analyzed for the expression of mouse K19 (mK19), human
K19 (hK19) and K19 pY391. Note that anti-K19 pY391 also recognizes the corresponding mouse isoform, K19 pY394. B. Hematoxylin and eosin
staining of colon tissues from untreated or PV-treated FVB/n mice demonstrating PV-induced tissue injury. C. The displayed immunofluorescence
images represent double-staining of the colons of untreated and PV-treated hK19 mice using antibodies to mouse K19 (mK19) and K19 pY391, which
also recognizes the mouse isoform, K19 pY394. Note the yellow staining after PV treatment due to K19 tyrosine phosphorylation after exposure of the
colon to PV.
doi:10.1371/journal.pone.0013538.g006
K19 Phosphorylation by Src
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[33]. The mass spectrometry-based phosphoproteomic peptide
analysis identified K19 tyrosine-130, located in the rod domain, as
the phosphorylation target. Although our initial in silico prediction
analysis of potential phosphorylation sites identified K19 Y130 as a
candidate, it received the second lowest score (Table S1).
Therefore, these data would need to be further validated
experimentally in order to clarify the physiological significance
of K19 pY130.
Despite prior demonstration of tyrosine phosphorylation of few
other IFs, the physiological significance of this type of modification
still remains to be elucidated. Upon stimulation with platelet-
derived growth factor (PDGF), vimentin filaments in porcine
aortic endothelial cells undergo reorganization, which is accom-
panied by an in increase in tyrosine phosphorylation [23].
However, the PDGF-induced filament reorganization was found
to be independent of tyrosine phosphorylation. Another potential
role for vimentin tyrosine phosphorylation is in chemokine-
mediated leukocyte extravasation, as demonstrated in a recent
study showing that CCL2 and CCL5 stimulate vimentin tyrosine
phosphorylation (the specific tyrosine residues are not known) and
filament disassembly, which is partially dependent upon PI3Kc
[24]. However, chemokine-mediated, PI3Kc -dependent vimentin
serine phosphorylation was observed concomitantly with vimentin
tyrosine phosphorylation in the context of this study [24], making
it difficult to dissect the specific role of each type of modification in
this context. Another study has demonstrated that rat PC12 cell
peripherin is constitutively phosphorylated at a reported C-
terminal tyrosine residue, but this modification is not critical for
filament assembly [22] and biochemical confirmation and
characterization of phosphorylation at the peripherin terminal
tyrosine has not been fully elucidated.
Therefore, IF tyrosine phosphorylation does not appear to play
an apparent role in IF network organization, which raises the
possibility that this modification serves other functions that remain
to be investigated such as the modulation of protein-protein
interactions. Such functions are likely to be dynamic since
detection of K19 tyrosine phosphorylation under a physiologic
or injury-related context has not been possible. For example, tissue
damage to the colon and pancreas induced by dextran sulphate
sodium (DSS) and a choline-deficient diet (CDD), respectively, as
well as exposure of cells to heat, H2O2, okadaic acid and
anisomycin all failed to produce detectable levels of K19 pY391
(data not shown), although such tissue and cell challenges do
stimulate marked keratin serine phosphorylation [16,19]. Addi-
tionally, acute treatment of HT29 cells with an alternative general
tyrosine phosphatase inhibitor (BVT 948), as well as selective
inhibitors of PTP1B (TCS 401), Cdc25 (NSC 95397), and shp1/2
(NSC 87877) protein phosphatases, failed to induce phosphory-
lation of K19 at tyrosine 391 similar to that observed in the
presence of pervanadate (Figure S2). Therefore, the K19 tyrosine
phosphorylation described herein does not appear to be regulated
by the cellular stress response in the various contexts tested here,
although its presence during pervanadate-induced tyrosine
phosphatase inhibition suggests that it is highly dynamic.
One plausible hypothesis that remains to be tested is that Src
kinase-mediated K19 tyrosine phosphorylation plays a role in the
oncogenic effects of this non-receptor tyrosine kinase [34]. The
metastatic potential of cancer cells, which correlates with a loss of
epithelial differentiation, is augmented in the presence of elevated
Src kinase activity [35]. Given that K19 has been shown to be a
target of oncogenic kinases in cancer, including Src [33], it is
possible that the phosphorylation of K19 Y391 is an event that
occurs during epithelial to mesenchymal transition and cancer
metastasis. Time-dependence and tissue-specific studies may
provide insight into the dynamics of regulation, as well as identify
additional tyrosine kinases that may be involved in the
phosphorylation of K19. The experimental evidence for Src
kinase–mediated phosphorylation of K19 provided herein, along
with the availability of the site-specific antibody which recognizes
pY391 K19 will enable future testing of this hypothesis.
Supporting Information
Table S1 Prediction of K19 tyrosine phosphorylation.
Found at: doi:10.1371/journal.pone.0013538.s001 (2.12 MB TIF)
Figure S1 Species-specific conservation of K19 Tyr391.
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Figure S2 The effect of acute treatment with different protein
tyrosine phosphatase inhibitors on K19 Y391 phosphorylation.
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